Effect of estrogen on calcium absorption and serum vitamin D metabolites in postmenopausal osteoporosis

John Christopher G. Gallagher, B. L. Riggs, H. F. DeLuca

Research output: Contribution to journalArticle

299 Citations (Scopus)

Abstract

Osteoporotic women have decreased calcium absorption and decreased serum 1,25-dihydroxyvitamin D [1,25-(OH)2D] and are usually in negative calcium balance. Estrogen therapy improves calcium balance in patients with postmenopausal osteoporosis. In birds, estrogen administration increases the conversion of 25-hydroxyvitamin D (25OHD) to 1,25-(OH)2D. To determine if estrogen therapy affects vitamin D metabolism in human subjects, we studied 21 osteoporotic women before and after 6 months of treatment. We compared groups treated with either placebo (9 patients) or conjugated equine estrogen (1.2-2.5 mg/day; 12 patients). Fractional calcium absorption (mean ± SE) was unchanged after treatment with placebo (0.51 ± 0.03 to 0.52 ± 0.01) but increased after treatment with estrogen (0.53 ± 0.02 to 0.65 ± 0.04; P2D (0.54 ± 0.03 to 0.68 ± 0.04; P2D was unchanged after treatment with placebo (27.5 ± 1.3 to 27.6 ± 1.7 pg/ml) but increased after treatment with estrogen (23.6 ± 2.7 to 33.2 ± 3.7 pg/ml; P2D were correlated (r=0.68; P2D and calcium absorption were highly correlated (r=0.89; P2D. This effect appears to be mediated indirectly through stimulation of renal 1α-hydroxylase by increased serum PTH.

Original languageEnglish
Pages (from-to)1359-1364
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume51
Issue number6
StatePublished - 1980

Fingerprint

Postmenopausal Osteoporosis
Metabolites
Vitamin D
Estrogens
Calcium
Serum
Placebos
Therapeutics
Conjugated (USP) Estrogens
Birds
Mixed Function Oxygenases
Metabolism
Kidney

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Effect of estrogen on calcium absorption and serum vitamin D metabolites in postmenopausal osteoporosis. / Gallagher, John Christopher G.; Riggs, B. L.; DeLuca, H. F.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 51, No. 6, 1980, p. 1359-1364.

Research output: Contribution to journalArticle

@article{2d5f108276194212860206a4a1d720dd,
title = "Effect of estrogen on calcium absorption and serum vitamin D metabolites in postmenopausal osteoporosis",
abstract = "Osteoporotic women have decreased calcium absorption and decreased serum 1,25-dihydroxyvitamin D [1,25-(OH)2D] and are usually in negative calcium balance. Estrogen therapy improves calcium balance in patients with postmenopausal osteoporosis. In birds, estrogen administration increases the conversion of 25-hydroxyvitamin D (25OHD) to 1,25-(OH)2D. To determine if estrogen therapy affects vitamin D metabolism in human subjects, we studied 21 osteoporotic women before and after 6 months of treatment. We compared groups treated with either placebo (9 patients) or conjugated equine estrogen (1.2-2.5 mg/day; 12 patients). Fractional calcium absorption (mean ± SE) was unchanged after treatment with placebo (0.51 ± 0.03 to 0.52 ± 0.01) but increased after treatment with estrogen (0.53 ± 0.02 to 0.65 ± 0.04; P2D (0.54 ± 0.03 to 0.68 ± 0.04; P2D was unchanged after treatment with placebo (27.5 ± 1.3 to 27.6 ± 1.7 pg/ml) but increased after treatment with estrogen (23.6 ± 2.7 to 33.2 ± 3.7 pg/ml; P2D were correlated (r=0.68; P2D and calcium absorption were highly correlated (r=0.89; P2D. This effect appears to be mediated indirectly through stimulation of renal 1α-hydroxylase by increased serum PTH.",
author = "Gallagher, {John Christopher G.} and Riggs, {B. L.} and DeLuca, {H. F.}",
year = "1980",
language = "English",
volume = "51",
pages = "1359--1364",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - Effect of estrogen on calcium absorption and serum vitamin D metabolites in postmenopausal osteoporosis

AU - Gallagher, John Christopher G.

AU - Riggs, B. L.

AU - DeLuca, H. F.

PY - 1980

Y1 - 1980

N2 - Osteoporotic women have decreased calcium absorption and decreased serum 1,25-dihydroxyvitamin D [1,25-(OH)2D] and are usually in negative calcium balance. Estrogen therapy improves calcium balance in patients with postmenopausal osteoporosis. In birds, estrogen administration increases the conversion of 25-hydroxyvitamin D (25OHD) to 1,25-(OH)2D. To determine if estrogen therapy affects vitamin D metabolism in human subjects, we studied 21 osteoporotic women before and after 6 months of treatment. We compared groups treated with either placebo (9 patients) or conjugated equine estrogen (1.2-2.5 mg/day; 12 patients). Fractional calcium absorption (mean ± SE) was unchanged after treatment with placebo (0.51 ± 0.03 to 0.52 ± 0.01) but increased after treatment with estrogen (0.53 ± 0.02 to 0.65 ± 0.04; P2D (0.54 ± 0.03 to 0.68 ± 0.04; P2D was unchanged after treatment with placebo (27.5 ± 1.3 to 27.6 ± 1.7 pg/ml) but increased after treatment with estrogen (23.6 ± 2.7 to 33.2 ± 3.7 pg/ml; P2D were correlated (r=0.68; P2D and calcium absorption were highly correlated (r=0.89; P2D. This effect appears to be mediated indirectly through stimulation of renal 1α-hydroxylase by increased serum PTH.

AB - Osteoporotic women have decreased calcium absorption and decreased serum 1,25-dihydroxyvitamin D [1,25-(OH)2D] and are usually in negative calcium balance. Estrogen therapy improves calcium balance in patients with postmenopausal osteoporosis. In birds, estrogen administration increases the conversion of 25-hydroxyvitamin D (25OHD) to 1,25-(OH)2D. To determine if estrogen therapy affects vitamin D metabolism in human subjects, we studied 21 osteoporotic women before and after 6 months of treatment. We compared groups treated with either placebo (9 patients) or conjugated equine estrogen (1.2-2.5 mg/day; 12 patients). Fractional calcium absorption (mean ± SE) was unchanged after treatment with placebo (0.51 ± 0.03 to 0.52 ± 0.01) but increased after treatment with estrogen (0.53 ± 0.02 to 0.65 ± 0.04; P2D (0.54 ± 0.03 to 0.68 ± 0.04; P2D was unchanged after treatment with placebo (27.5 ± 1.3 to 27.6 ± 1.7 pg/ml) but increased after treatment with estrogen (23.6 ± 2.7 to 33.2 ± 3.7 pg/ml; P2D were correlated (r=0.68; P2D and calcium absorption were highly correlated (r=0.89; P2D. This effect appears to be mediated indirectly through stimulation of renal 1α-hydroxylase by increased serum PTH.

UR - http://www.scopus.com/inward/record.url?scp=0019209377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019209377&partnerID=8YFLogxK

M3 - Article

C2 - 6255005

AN - SCOPUS:0019209377

VL - 51

SP - 1359

EP - 1364

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 6

ER -